BioPharmSignal logoBioPharmSignal

Biotech News

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta (EMBC)EmbectaEarnings

PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.

Related news

EMBCEmbecta2026-07-23 21:00 EST

embecta to Report Fiscal Third Quarter Financial Results

EMBCEmbecta2026-05-05 10:30 EST

Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

View all latest news

Embecta

Global Diabetes Care Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management. Injection-Device Portfolio The company's core portfolio includes pen needles and...

Recent company news

EMBCEmbecta2026-08-07 10:30 EST

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

EMBCEmbecta2026-08-07 10:00 EST

embecta Announces Quarterly Cash Dividend

EMBCEmbecta2026-07-23 21:00 EST

embecta to Report Fiscal Third Quarter Financial Results

EMBCEmbecta2026-06-16 10:30 EST

embecta appoints Nimish Muzumdar as SVP and President, North America

EMBCEmbecta2026-06-01 21:00 EST

embecta to Participate in Investor Events

Stock data

Close
3.50 USD
Market cap
207.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States